FDA clears Evident Vascular's AI-powered system for seeing inside arteries

Evident Vascular said on Wednesday, Nov. 4, 2026, that the FDA granted 510(k) clearance to its Evident Vascular Guidance System and Evident peripheral imaging catheters, an AI-powered intravascular ultrasound (IVUS) platform for peripheral vascular procedures.

IVUS is how interventionalists check what a blood vessel actually looks like before they balloon or stent it, and the pitch here is sharper pictures with less fuss, not a robot doctor. The AI is mostly in the plumbing for now; the company says more FDA submissions come next. And a clearance is not a launch: the company says it can't sell the thing yet.

The FDA granted 510(k) clearance to the Evident Vascular Guidance System and to Evident's peripheral imaging catheters. A 510(k) is the path the agency uses when it decides a device is close enough to one already allowed on the market. The system is for ultrasound examination of intravascular pathology during peripheral vascular interventions. Intravascular means inside a blood vessel. Pathology, here, is disease in the vessel wall. Peripheral means arteries away from the heart, in the legs and elsewhere, rather than the coronary arteries that feed the heart muscle. Those lines are the clearance's, as Evident reported them.

IVUS is intravascular ultrasound. It puts a tiny ultrasound probe on the end of a catheter, a thin tube, so a physician can image a blood vessel from the inside during a procedure. The view is a cross-section of the artery, taken from within it, before a balloon or a stent goes in.

Evident says the catheters are flushless and plug-and-play. Flushless means they do not need a rinse of saline, salt water, before they will make a picture. Plug-and-play means they connect and are ready, without a long setup. The system has an intuitive interface and hands-free voice control, so the physician can run tasks without taking a hand off the procedure. Those lines are Evident's.

Evident calls the pictures high-fidelity. They are built around proprietary DFC technology, short for dynamic frequency control, and purpose-built AI. Frequency is how the ultrasound is tuned. One setting is rarely best for every vessel and every depth, so dynamic frequency control is meant to hold detail and reach at the same time, across the field of view. Those lines are Evident's.

The platform pairs custom imaging electronics with real-time image processing on NVIDIA accelerated computing. Accelerated computing means the heavy image math runs on NVIDIA chips, not on a general processor alone. Evident is a member of NVIDIA's Inception startup program. The system runs a proprietary AI workstation, and Evident says it plans to add more AI features as clinical experience and the data from procedures grow. Those lines are Evident's. The images are there for the physician. Evident does not say the software makes the diagnosis or picks the treatment.

Howard Rosen, chief executive and co-founder, said: "We engineered the entire imaging architecture to deliver the image fidelity physicians need in a system that is both intuitive and easy to use." Eric A. Secemsky, MD, of Beth Israel Deaconess Medical Center, said: "The vessel-edge clarity and consistency across the field of view are remarkable." Justin Klein, MD, JD, of Vensana Capital, a founder and board director of Evident, said: "This clearance establishes an important foundation for further FDA submissions." Those quotations are theirs.

Evident says the system and the catheters are not yet available for sale in the United States or in any other jurisdiction. Clearance is permission. It is not a product a hospital can order. Those lines are Evident's.

The picture is the Evident Vascular Guidance System: a white rolling cart with a mounted touchscreen, beside a tablet on a stand showing a grayscale intravascular ultrasound cross-section of a blood vessel. The credit is Evident Vascular.

In plain terms, the FDA cleared Evident's ultrasound cart and catheters for looking at disease inside a peripheral artery while a procedure is underway. The pitch is a sharper picture, a simpler catheter, and voice control, with NVIDIA hardware doing the image math. More AI features, and more submissions to the FDA, are what the company says comes next. It also says it cannot sell the system yet.